Cannabidiol (CBD) is the most abundant nonpsychoactive cannabinoid in cannabis. Animal studies demonstrate anticonvulsant efficacy in multiple species and models. Anecdotal reports suggest CBD to be
effective in children with treatment-resistant epilepsies (TRE), especially Dravet syndrome (DS). We report results of an open label study in children with TRE in an expanded access treatment program conducted in the US under INDs. Efficacy results are reported for all patients who received at least 12 weeks of treatment (n=137). Safety
results are reported for all patients who received any
treatment (n=213)
